From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier

Impact of Pristine Graphene on Intestinal Microbiota Assessed Using a Bioreactor-Rotary Cell Culture System

The increased use of graphene in consumer products such as food contact materials requires a thorough understanding of its effects on the gastrointestinal commensal bacterial population. During the first phase of study, three representative commensal bacterial species (L. acidophilus, B. longum, and E. coli) were exposed to different concentrations (1, 10, and 100 μg/mL) of pristine graphene for 3, 6, and 24 h in the Bioreactor Rotary Cell Culture System (BRCCS) which allowed a continuous interaction of intestinal microbiota with the pristine graphene without precipitation of test material. The results showed that pristine graphene had dose-dependent effects on the growth of selective bacteria. To study the interaction of graphene with more diverse consortia of intestinal microbiota, fresh fecal samples from laboratory rats were used. Rat fecal slurry (3%) was maintained in an anaerobic environment and treated with different concentrations (1, 10, and 100 μg/mL) of pristine graphene for 3, 6, and 24 h. Counts of viable aerobic and anaerobic bacteria were assessed and fecal slurries were also collected for microbial population shift analysis using quantitative real-time PCR, as well as 16s rRNA sequencing. The results showed a significant two-fold increase in both aerobic and anaerobic bacterial counts (expressed as colony forming unit; CFU) during the first 3 h of exposure to all pristine graphene concentrations. However, 24 h of continuous exposure resulted in a 120% decrease in the CFU of aerobic bacteria at the highest concentration and the anaerobic bacteria CFU remained unchanged. Multivariate analysis of the q-PCR data showed that the exposure time, as well as the graphene concentrations, impacted the bacterial population abundance. Community analysis of graphene-treated fecal samples by 16S sequencing revealed significant alteration of 15 taxonomic groups, including 9 species. The increased abundance of butyrate-producing bacteria (Clostridium fimetarium, Clostridium hylemona, and Sutterella wadsworthensis) was correlated with an increase of the short-chain fatty acid, butyric acid after exposure to graphene. These results clearly indicate that graphene may cause adverse effects on the intestinal microbiome at the doses equal to 100 μg/mL. Further experiments using ex vivo intestinal explants (nonanimal model) could reveal the mechanisms by which graphene could perturb the microbe-host intestinal mucosa homeostasis.

Detection of nanocarrier potentiation on drug induced phospholipidosis in cultured cells and primary hepatocyte spheroids by high content imaging and analysis

Considerable effort has been made to develop nanocarriers for controlled drug delivery over the last decade, while it remains unclear how the strength of adverse drug effect will be altered when a drug is loaded on the nanocarrier. Drug-induced phospholipidosis (DIP) is characterized with excessive accumulation of phospholipids in cells and is common for cationic amphiphilic drugs (CAD). Previously, we have reported that PEGylated graphene oxide (PEG-GO) loaded with several CAD can potentiate DIP. In current study, we extended our study on newly identified phospholipidosis (PLD) inducers that had been identified from the Library of Pharmacologically Active Compounds (LOPAC), to investigate if PEO-GO loaded with these CAD can alter DIP. Twenty-two CAD were respectively loaded on PEG-GO and incubated with RAW264.7, a macrophage cell line. The results showed that when a CAD was loaded on PEG-GO, its strength of PLD induction can be enhanced, unchanged or attenuated. PEG-GO loaded with Ifenprodil exhibited the highest PEG-GO potentiation effect compared to Ifenprodil treatment alone in RAW264.7 cells, and this effect was confirmed in human hepatocellular carcinoma HepG2, another cell line model for PLD induction. Primary hepatocyte culture and spheroids mimicking in vivo conditions were used to further validate nanocarrier potentiation on DIP by Ifenprodil. Stronger phospholipid accumulation was found in PEG-GO/Ifenprodil treated hepatocytes or spheroids than Ifenprodil treatment alone. Therefore, evidences were provided by us that nanocarriers may increase the adverse drug effects and guidance by regulatory agencies need to be drafted for the safe use of nanotechnology in drug delivery.

Antiviral activity of cationic amphiphilic drugs

Introduction: Emerging and reemerging viral infections represent a major concern for human and veterinary public health and there is an urgent need for the development of broad-spectrum antivirals.

Areas covered: A recent strategy in antiviral research is based on the identification of molecules targeting host functions required for infection of multiple viruses. A number of FDA-approved drugs used to treat several human diseases are cationic amphiphilic drugs (CADs) that have the ability to accumulate inside cells affecting several structures/functions hijacked by viruses during infection. In this review we summarized the CADs’ chemical properties and effects on the cells and reported the main FDA-approved CADs that have been identified so far as potential antivirals in drug repurposing studies.

Expert commentary: Although there have been concerns regarding the efficacy and the possible side effects of the off-label use of CADs as antivirals, they seem to represent a promising starting point for the development of broad-spectrum antiviral strategies. Further knowledge about their mechanism of action is required to improve their antiviral activity and to reduce the risk of side effects.

Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents

Engineered nanomaterials (ENMs), or small anthropogenic particles approximately < 100 nm in size and of various shapes and compositions, are increasingly incorporated into commercial products and used for industrial and medical purposes. There is an exposure risk to both the population at large and individuals in the workplace with inhalation exposures to ENMs being a primary concern. Further, there is increasing evidence to suggest that certain ENMs may represent a significant health risk, and many of these ENMs exhibit distinct similarities with other particles and fibers that are known to induce adverse health effects, such as asbestos, silica, and particulate matter (PM). Evidence regarding the importance of lysosomal membrane permeabilization (LMP) and release of cathepsins in ENM toxicity has been accumulating. The aim of this review was to describe our current understanding of the mechanisms leading to ENM-associated pathologies, including LMP and the role of cathepsins with a focus on inflammation. In addition, anti-cathepsin agents, some of which have been tested in clinical trials and may prove useful for ameliorating the harmful effects of ENM exposure, are examined.